Tanycytes in Alzheimer's Disease and Frontotemporal Dementia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-85
SponsorUniversity Hospital, Lille

About this trial

Metabolic and hormonal deregulations are both a risk factor and a hallmark of Alzheimer's disease (AD) and frontotemporal dementia (FTD), occurring early in the course of the disease. In FTD in particular, hyperorality and dietary changes are associated with metabolic and hormonal changes such as altered levels of the anorexigenic hormone leptin.

The hypothalamus is a brain region that controls metabolism and hormonal systems. Hypothalamic function depends on its ability to sense peripheral signals. The hypothalamus sits on a circumventricular organ called the median eminence (ME) that puts it in contact with systemic blood circulation. In the ME, fenestrated capillaries allow the diffusion of bloodborne factors. However, despite the lack of blood-brain barrier at brain microvessels, diffusion is controlled by specialized ependymoglial cells, the tanycytes, which exert a barrier function between the ME and the third ventricle and controls the access of blood-borne molecules into the hypothalamus. Previous work from our laboratory and the ERC consortium has highlighted the role of tanycytes not only in the regulation of the release of neurohormones from neuroendocrine nerve terminals into the pituitary portal blood circulation, but also in the transport of circulating leptin into the hypothalamus. Hence hypothalamic dysfunction in AD and FTD can result either from dysregulation of neuroendocrine secretions, direct neuronal loss or from defective transport (and hence resistance) to hormones like leptin.

This study is to demonstrate that leptin transport though tanycytes is early altered in FTD and AD and correlates

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Subjects able to undergo a lumbar puncture

Subjects registered with the French Social Security, in agreement with the French law on biomedical experimentation

absence of cognitive complaint (completion of the memory complaint questionnaire)

absence of significant cognitive impairment: normal MMSE according to age and education levels

Disqualifiers

Subjects with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load

Subjects who have contraindications to perform a lumbar puncture

Subjects who have contraindications to perform a MRI scan

Weighted less than 45 kg

Trial population

Subjects intended to participate will be recruited in Lille in the memory clinic and in the memory clinic network Meotis (North of France above Paris)

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Lumbar puncture

    Biological/Vaccine

    5 mL of CSF

  • blood sample

    Biological/Vaccine

    6x5 mL of blood sample collected :1 dry tube, 2 EDTA tubes, 1 fluoride tube, and 2 polypropylene tubes

Treatment groups

102 Participants
are divided into 3 treatment groups
Group A: Group 1: Controls2 interventions
Group B: Group 2: Alzheimer's Disease2 interventions
Group C: Group 3: Frontotemporal Dementia2 interventions

Trial outcomes

Primary outcomes

1

Mean CSF-to-blood ratio (CBR) of leptin concentration.

Leptin concentration in blood and CSF (in the pg/mL range) will be measured by enzyme-linked immunosorbent assay (ELISA).

Time frame
At visit 2, occurring 1 to 90 days after visit 1(Baseline)

Secondary outcomes

1

Mean of the CSF-to-blood ratio (CBR) of hypothalamus-related hormones

CSF-to-blood ratio (CBR) of hypothalamus-related hormones

Time frame
At visit 2, occurring 1 to 90 days after visit 1(Baseline)
2

Blood metabolomics

Blood and CSF metabolites will be measured by LC MS/MS.Will be used a mix of targeted and untargeted approach for metabolomics using the Thermo Q-Exactive Orbitrap.

Time frame
At visit 2, occurring 1 to 90 days after visit 1(Baseline)
3

CSF metabolomics

Blood and CSF metabolites will be measured by LC MS/MS.Will be used a mix of targeted and untargeted approach for metabolomics using the Thermo Q-Exactive Orbitrap.

Time frame
At visit 2, occurring 1 to 90 days after visit 1(Baseline)
4

Correlation coefficient between leptin CBR and general cognitive functioning assessed by the Mattis Dementia Rating Scale (MDRS)6

Correlation coefficient between leptin CBR and general cognitive functioning

Time frame
At visit 2, occurring 1 to 90 days after visit 1(Baseline)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Lille

Lead sponsor

European Research Council

Collaborator

CH Calais

Collaborator

Centre Hospitalier VALENCIENNES

Collaborator

Région Nord-Pas de Calais, France

Collaborator

Centre Hospitalier de Bethune

Collaborator